DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Tamura K, Shitara K, Naito Y. et al.
Single Agent Activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: phase 1 dose escalation. ESMO 2016.
Ann Oncol 2016;
27: 1-36 LBA 17
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.